Inequity in access to personalized medicine in France: Evidences from analysis of geo variations in the access to molecular profiling among advanced non-small-cell lung cancer patients: Results from the IFCT Biomarkers France Study


  • Kembou Nzale Samuel
  • Weeks William
  • Ouafik L’houcine
  • Rouquette Isabelle
  • Beau-Faller Michèle
  • Lemoine Antoinette
  • Bringuier Pierre-Paul
  • Le Coroller Soriano Anne-Gaëlle
  • Barlesi Fabrice
  • Ventelou Bruno


  • Lung and intrathoracic tumors
  • France
  • Genetic testing
  • Non-small cell lung cancer
  • Human genetics
  • Physicians
  • Biogeography
  • Personalized medicine

document type



In this article, we studied geographic variation in the use of personalized genetic testing for advanced non-small cell lung cancer (NSCLC) and we evaluated the relationship between genetic testing rates and local socioeconomic and ecological variables. We used data on all advanced NSCLC patients who had a genetic test between April 2012 and April 2013 in France in the frame of the IFCT Biomarqueurs-France study (n = 15814). We computed four established measures of geographic variation of the sex-adjusted rates of genetic testing utilization at the "dé partment" (the French territory is divided into 94 administrative units called 'dé partements') level. We also performed a spatial regression model to determine the relationship between dé partement-level sex-adjusted rates of genetic testing utilization and economic and ecological variables. Our results are the following: (i) Overall, 46.87% lung cancer admission patients obtained genetic testing for NSCLC; dé partement-level utilization rates varied over 3.2-fold. Measures of geographic variation indicated a relatively high degree of geographic variation. (ii) there was a statistically significant relationship between genetic testing rates and per capita supply of general practitioners, radiotherapists and PLOS ONE

more information